Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis.
Toyoda H, Hiraoka A, Tada T, Michitaka K, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S, Kumada T. Toyoda H, et al. Among authors: taniguchi t. Ther Apher Dial. 2017 Oct;21(5):465-472. doi: 10.1111/1744-9987.12563. Epub 2017 Sep 7. Ther Apher Dial. 2017. PMID: 28880488
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, Fujimoto S, Kimura T, Okamoto K, Miyamoto H, Muguruma N, Takayama T. Tomonari T, et al. Among authors: taniguchi t. Oncotarget. 2016 Feb 9;7(6):7207-15. doi: 10.18632/oncotarget.6889. Oncotarget. 2016. PMID: 26769852 Free PMC article.
Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation.
Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S; Real-Life Practice Experts For Hepatocellular Carcinoma (HCC) (RELPEC) Study Group and The HCC 48 Group (HCC experts from 48 clinics). Hiraoka A, et al. Among authors: taniguchi t. Mol Clin Oncol. 2017 Apr;6(4):455-461. doi: 10.3892/mco.2017.1192. Epub 2017 Mar 10. Mol Clin Oncol. 2017. PMID: 28413650 Free PMC article.
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
Tomonari T, Sato Y, Tani J, Hirose A, Ogawa C, Morishita A, Tanaka H, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Uchida K, Masaki T, Takayama T. Tomonari T, et al. Among authors: taniguchi t. Hepatol Res. 2021 Apr;51(4):472-481. doi: 10.1111/hepr.13597. Epub 2021 Mar 1. Hepatol Res. 2021. PMID: 33238074
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis.
Ochi H, Tani J, Tomonari T, Taniguchi T, Koizumi Y, Hirose A, Ogawa C, Hiraoka A, Morishita A, Moriya A, Hirooka M, Deguchi A, Symple Study Group. Ochi H, et al. Among authors: taniguchi t. Hepatol Res. 2021 Dec;51(12):1219-1228. doi: 10.1111/hepr.13713. Epub 2021 Sep 29. Hepatol Res. 2021. PMID: 34534398
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
Tomonari T, Tani J, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Asahiro M, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Masaki T, Takayama T. Tomonari T, et al. Among authors: taniguchi t. Cancer Med. 2023 Feb;12(3):2646-2657. doi: 10.1002/cam4.5145. Epub 2022 Aug 14. Cancer Med. 2023. PMID: 35964253 Free PMC article.
4,600 results